Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma

Allan Norman Krutchik, Aman U. Buzdar, George R. Blumenschein, Gabriel N. Hortobagyi, Charles K. Tashima, Jordan U. Gutterman, H. Y. Yap, Evan M. Hersh

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Thirty‐two patients with a diagnosis of primary inflammatory breast carcinoma were treated with combination chemoimmunotherapy consisting of 5‐fluorouracil, doxorubicin hydrochloride (Adria‐mycin), and cyclophosphamide (FAC) plus BCG followed by radiation therapy. This group of patients was compared to a group of 32 consecutive historical controls treated with radiation therapy alone. The estimated mean disease‐free interval for the FAC‐BCG group was 16 months, compared to 9 months for the radiation therapy alone group (P <0.01). The estimated median survival for the FAC‐ BCG treated group was 24 months, compared to 18 months for the radiation therapy alone group (P = 0.03). The combined modality approach consisting of chemoimmunotherapy and radiation therapy significantly improved the disease‐free interval and survival of patients with inflammatory breast carcinoma.

Original languageEnglish (US)
Pages (from-to)325-332
Number of pages8
JournalJournal of Surgical Oncology
Volume11
Issue number4
DOIs
StatePublished - Jan 1 1979

Fingerprint

Inflammatory Breast Neoplasms
Radiotherapy
Mycobacterium bovis
Doxorubicin
Survival
Cyclophosphamide

Keywords

  • breast carcinoma
  • chemoimmunotherapy
  • disease‐free interval an
  • inflammatory
  • irradiation
  • surviva

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Krutchik, A. N., Buzdar, A. U., Blumenschein, G. R., Hortobagyi, G. N., Tashima, C. K., Gutterman, J. U., ... Hersh, E. M. (1979). Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. Journal of Surgical Oncology, 11(4), 325-332. https://doi.org/10.1002/jso.2930110407

Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. / Krutchik, Allan Norman; Buzdar, Aman U.; Blumenschein, George R.; Hortobagyi, Gabriel N.; Tashima, Charles K.; Gutterman, Jordan U.; Yap, H. Y.; Hersh, Evan M.

In: Journal of Surgical Oncology, Vol. 11, No. 4, 01.01.1979, p. 325-332.

Research output: Contribution to journalArticle

Krutchik, AN, Buzdar, AU, Blumenschein, GR, Hortobagyi, GN, Tashima, CK, Gutterman, JU, Yap, HY & Hersh, EM 1979, 'Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma', Journal of Surgical Oncology, vol. 11, no. 4, pp. 325-332. https://doi.org/10.1002/jso.2930110407
Krutchik AN, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Gutterman JU et al. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. Journal of Surgical Oncology. 1979 Jan 1;11(4):325-332. https://doi.org/10.1002/jso.2930110407
Krutchik, Allan Norman ; Buzdar, Aman U. ; Blumenschein, George R. ; Hortobagyi, Gabriel N. ; Tashima, Charles K. ; Gutterman, Jordan U. ; Yap, H. Y. ; Hersh, Evan M. / Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. In: Journal of Surgical Oncology. 1979 ; Vol. 11, No. 4. pp. 325-332.
@article{d57b5e6310ef4ee5a9dce6cf7bb480bb,
title = "Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma",
abstract = "Thirty‐two patients with a diagnosis of primary inflammatory breast carcinoma were treated with combination chemoimmunotherapy consisting of 5‐fluorouracil, doxorubicin hydrochloride (Adria‐mycin), and cyclophosphamide (FAC) plus BCG followed by radiation therapy. This group of patients was compared to a group of 32 consecutive historical controls treated with radiation therapy alone. The estimated mean disease‐free interval for the FAC‐BCG group was 16 months, compared to 9 months for the radiation therapy alone group (P <0.01). The estimated median survival for the FAC‐ BCG treated group was 24 months, compared to 18 months for the radiation therapy alone group (P = 0.03). The combined modality approach consisting of chemoimmunotherapy and radiation therapy significantly improved the disease‐free interval and survival of patients with inflammatory breast carcinoma.",
keywords = "breast carcinoma, chemoimmunotherapy, disease‐free interval an, inflammatory, irradiation, surviva",
author = "Krutchik, {Allan Norman} and Buzdar, {Aman U.} and Blumenschein, {George R.} and Hortobagyi, {Gabriel N.} and Tashima, {Charles K.} and Gutterman, {Jordan U.} and Yap, {H. Y.} and Hersh, {Evan M.}",
year = "1979",
month = "1",
day = "1",
doi = "10.1002/jso.2930110407",
language = "English (US)",
volume = "11",
pages = "325--332",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma

AU - Krutchik, Allan Norman

AU - Buzdar, Aman U.

AU - Blumenschein, George R.

AU - Hortobagyi, Gabriel N.

AU - Tashima, Charles K.

AU - Gutterman, Jordan U.

AU - Yap, H. Y.

AU - Hersh, Evan M.

PY - 1979/1/1

Y1 - 1979/1/1

N2 - Thirty‐two patients with a diagnosis of primary inflammatory breast carcinoma were treated with combination chemoimmunotherapy consisting of 5‐fluorouracil, doxorubicin hydrochloride (Adria‐mycin), and cyclophosphamide (FAC) plus BCG followed by radiation therapy. This group of patients was compared to a group of 32 consecutive historical controls treated with radiation therapy alone. The estimated mean disease‐free interval for the FAC‐BCG group was 16 months, compared to 9 months for the radiation therapy alone group (P <0.01). The estimated median survival for the FAC‐ BCG treated group was 24 months, compared to 18 months for the radiation therapy alone group (P = 0.03). The combined modality approach consisting of chemoimmunotherapy and radiation therapy significantly improved the disease‐free interval and survival of patients with inflammatory breast carcinoma.

AB - Thirty‐two patients with a diagnosis of primary inflammatory breast carcinoma were treated with combination chemoimmunotherapy consisting of 5‐fluorouracil, doxorubicin hydrochloride (Adria‐mycin), and cyclophosphamide (FAC) plus BCG followed by radiation therapy. This group of patients was compared to a group of 32 consecutive historical controls treated with radiation therapy alone. The estimated mean disease‐free interval for the FAC‐BCG group was 16 months, compared to 9 months for the radiation therapy alone group (P <0.01). The estimated median survival for the FAC‐ BCG treated group was 24 months, compared to 18 months for the radiation therapy alone group (P = 0.03). The combined modality approach consisting of chemoimmunotherapy and radiation therapy significantly improved the disease‐free interval and survival of patients with inflammatory breast carcinoma.

KW - breast carcinoma

KW - chemoimmunotherapy

KW - disease‐free interval an

KW - inflammatory

KW - irradiation

KW - surviva

UR - http://www.scopus.com/inward/record.url?scp=0018749614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018749614&partnerID=8YFLogxK

U2 - 10.1002/jso.2930110407

DO - 10.1002/jso.2930110407

M3 - Article

C2 - 109703

AN - SCOPUS:0018749614

VL - 11

SP - 325

EP - 332

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -